UCB SA Reports Non-GAAP EPS of €6.84 and Revenue Growth to €4.27 Billion
UCB SA reported a non-GAAP earnings per share (EPS) of €6.84 for the first half, with revenue reaching €4.27 billion, representing a year-over-year increase of 22.3%. The company also noted that adjusted EBITDA rose to €1.736 billion in H1 2026, reflecting growth rates of +68% and +79% compared to the previous period. UCB SA has updated its financial guidance for FY2026 amid continued strong performance. The company attributes this robust growth to ongoing operational improvements and market demand across its therapeutic areas.
Tickers: $UCB
Topics: Earnings EBITDA Revenue Growth